The spotlight on drug costs continues to intensify as Mylan NV joins the ranks of generic and branded Rx firms being investigated by the Department of Justice for their pricing practices.
The firm announced in an 8-K filing that it had received a subpoena on Dec. 3 from the antitrust division of the Department of Justice seeking information relating to the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?